National and Kapodistrian University of Athens
Η σημασία της ιστοχημικής ανιχνεύσεως των περιοχών οργανώσεως του πυρηνίου (AgNORs) και της ανοσοϊστοχημικής καταδείξεως του πυρηνικού αντιγόνου πολλαπλασιαζομένων κυττάρων (PCNA) και της εκφράσεως των ογκογονιδίων c-myc και Ha-ras στο πολλαπλούν μυέλωμα: μελέτη σε 180 οστεομυελικές βιοψίες
Abstract
dc:descriptionWe have studied 180 cases of Multiple Myeloma, 176 of which concerned bone marrow trephine biopsies and 4 solitary extramedullar plasmacytomas. Our material, was formalin-fixed, paraffin-embedded tissue sections of 4ηιμ thick which were initially studied by using conventional histochemical methods and further on with the standard immunoperoxidase methods of peroxidase-antiperoxidase, avidin-biotin-peroxidase complex (ABC) and Streptavidin-biotin-peroxidase complex (Strepi ABC). We have also performed the colloidal silver staining method for the demon stration of the argyrophilic nucleolar organizer regions (AgNORs). The antibodies used to carry out the above mentioned methods were the following: 1. Polyclonal antibodies against the immunoglobulin κ and λ light chains. 2. Polyclonal antibodies against the immunoglobulin heavy chains: IgG, IgA, IgM, IgD, IgE. 3. Monoclonal antibody L-26 which recognizes the homonym antigenic determinant. 4. Monoclonal antibody 1-9E10 which identifies the p62 protein, encoded by the c-myc oncogene. 5. Monoclonal antibody Y13 259 which identifies the p21 protein encoded by the Ha-ras oncogene. 6. Monoclonal antibody PC-10 against the Proliferating Cell Nuclear Antig en/Cyclin. The aim of our study was to investigate the following: a) the expression of the oncogenes c-myc and Ha-ras in Multiple Myeloma (M.M.), b) the evaluation of the utility of the monoclonal antibody PC-10 in the determination of the biological behaviour of this malignant neoplasm, c) the evaluation of the AgNORs count in the histological grading of M.M. d) the specificity of the monoclonal antibody L-26 in differentiation of M.M. from other Β cell lymphoproliferative disorders and finally e) the necessity of immunohistochemical methods to evaluate the immunophenotype of malignant plasmacytes in M.M. The results concerning the above antibodies expression in M.M. are summarized as follows: 1. L-26 Monoclonal antibody is a very specific and sensitive marker for B-cell malignancies except for Multiple Myeloma which is lacking this antigen. Therefore it might be helpful in the differential diagnosis of M.M. from other B-cell malignancies. 2. The IgG immunophenotype is the commonest one met in Multiple Myeloma. 3. The evaluation of the morphology of the neoplastic plasma cells as a unique criterion for the immunophenotype of M.M. should be avoided and immunohistochemistry must always be performed for the identification of the M-protein produced by malignant plasmacytes. 4. The number of AgNORs although considered as a good prognostic marker must not be evaluated as such, but in association with other prognostic clinical and/or laboratory findings and markers. 5. The PC-10 monoclonal antibody, is a particularly reliable and specific marker in the evaluation of proliferation status of M.M. cells and hence of its biological behaviour. 6. The immunohistochemical expression of c-myc oncogene, correlates strongly with these of the PC-10 and the AgNORs count and hence, with the proliferation status of M.M. It is noteworthy that the c-myc Pgg protein, expressed in malignant plasmacytes, does not show any relevance with their morphology and infiltration patterns of bone marrow. 7. The expression of Ha-ras oncogene at the immunohistochemical level, is probably related to the pathogenesis of M.M.(its correlation with c-myc being statistically indicative). Its quantitative level does not appear to correlate with the morphology of plasmacytes and/or infiltration patterns and hence with the histological grade of malignancy of M.M. However, the relationship between its expression level and the biological behaviour of this neoplasm, might not be excluded independently of the histological grade or other prognostic markers; this is a matter of further investigation for the molecular biologists and immuno-cytogenetics.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 1991
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Skopelitou, Antigone
- Σκοπελίτου, Αντιγόνη
Subjects
dc:subject × 30- Πολλαπλούν μυέλωμα
- Ανοσοσφαιρίνες
- Περιοχές οργανώσεως του πυρηνίου
- Πυρηνικό αντιγόνο πολλαπλασιαζόμενων κυττάρων
- Ογκογονίδια
- Άνοσοϊστοχημικές χρώσεις
- Ιστοχημικές χρώσεις
- Τομές παραφίνης
- Πλασματοκύτταρα
- Πλασματοκυτταρικές δυσκρασίες
- Multiple myeloma
- Extramedullary plasmacytoma
- Bone marrow
- Plasma cells
- Biopsy
- Plasma cell dyscrasias
- Immunohistochemistry ( IHC)
- Oncogenes
- C-myc
- ras
- AgNORs
- PCNA
- Nucleolar organizer regions
- Proliferating cell nuclear antigen
- Paraffin sections
- Histochemistry
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26718